December 10, 2007 - Targacept, Inc. (Nasdaq: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), announced that it has initiated a Phase I clinical trial of its product candidate TC-6499. The initiation of the trial triggers a $6.0 million milestone payment to Targacept under the terms of its alliance agreement with GlaxoSmithKline...Neuropathic pain is characterized as severe, stabbing, burning or tingling and is most often associated with diabetes mellitus... Targacept's Press Release -
